A PHARMACOGENOMIC APPROACH TO ANTIPLATELET THERAPY IN STEMI PATIENTS: REASSESSMENT OF ANTI-PLATELET THERAPY USING AN INDIVIDUALIZED STRATEGY IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (THE RAPID STEMI STUDY)

A PHARMACOGENOMIC APPROACH TO ANTIPLATELET THERAPY IN STEMI PATIENTS: REASSESSMENT OF ANTI-PLATELET THERAPY USING AN INDIVIDUALIZED STRATEGY IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (THE RAPID STEMI STUDY)

Patients without at-risk genetic variants (N=43) At-risk patients randomized to Prasugrel (N=30) At-risk patients randomized to High-dose Clopidogrel (N=29) p-value[dagger] Primary Outcome

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2013-03, Vol.61 (10), p.E5-E5
Hauptverfasser: So, Derek Yiu Fai, Wells, George, McPherson, Ruth, Labinaz, Marino, Glover, Chris, May, Michel Le, Dick, Alexander, Froeschl, Michael, Marquis, Jean-Francois, Garg, Nitan, Bernick, Jordan, Tran, Luan, Hibbert, Benjamin, Roberts, Jason
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cardiovascular
Heart attacks
Internal Medicine
Medical research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients without at-risk genetic variants (N=43) At-risk patients randomized to Prasugrel (N=30) At-risk patients randomized to High-dose Clopidogrel (N=29) p-value[dagger] Primary Outcome
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(13)60006-6